Jardiance Gets Heart Failure Nod, But How Long Will Its Reign Last?
Executive Summary
The SGLT2 inhibitor has better efficacy and clearer labeling than Novartis’s Entresto in heart failure with preserved ejection fraction, but AstraZeneca’s Farxiga is expected to produce Phase III data by June.
You may also be interested in...
Jardiance, Trajenta Wins: Boehringer Takes Rough With Smooth In India
Boehringer Ingelheim tackles infringement activity pertaining to Trajenta and Jardiance in India, at least for now, but more action appears to be in the wings. The private German group remains confident that Jardiance will retain its preferred treatment choice status in the country for type 2 diabetes - but can the blockbuster therapy shake up the heart failure segment as well?
Late-Stage Pipeline Blooming At Boehringer As R&D Spend Soars
Over the next five years, the German group is looking to invest over €25bn in the R&D pipeline, with oncology a key focus.
After Jardiance Heart Failure Successes, BI And Lilly Focus On Kidney
Jardiance, the best-selling SGLT2 inhibitor, has AstraZeneca’s same-class rival Farxiga firmly in its sights in renal disease after showing such a level of efficacy that the 6,600-patient EMPA-KIDNEY study has been halted.